DSpace width= university logo mark
Japanese | English 

KURA > C. 医薬保健学域・研究域/医・薬学部/医学系研究科 > c10. 学術雑誌掲載論文(医・保健) > 1. 査読済論文(医学・保健) >

全文を表示する

ファイル 記述 サイズフォーマット
ME-PR-TAKUWA-Y-1205.pdf1.53 MBAdobe PDF
見る/開く
タイトル: Sphingosine-1-phosphate receptor 2 protects against anaphylactic shock through suppression of endothelial nitric oxide synthase in mice
著者: Cui, Hong
Okamoto, Yasuo link image
Yoshioka, Kazuaki link image link image
Du, Wa
Takuwa, Noriko link image link image
Zhang, Wei
Asano, Masahide link image
Shibamoto, Toshishige link image link image
Takuwa, Yoh link image link image
岡本, 安雄
浅野, 雅秀
多久和, 陽
発行日: 2013年11月
出版社(者): Elsevier
雑誌名: Journal of Allergy and Clinical Immunology
ISSN: 0091-6749
巻: 132
号: 5
開始ページ: 1205
終了ページ: 1214
キーワード: β-catenin
adherens junction
anaphylaxis
endothelial nitric oxide synthase
nitric oxide
nitrosylation
S1P2
phingosine-1-phosphate
vascular permeability
VE-cadherin
抄録: Background Sphingosine-1-phosphate receptor 2 (S1P2) is expressed in vascular endothelial cells (ECs). However, the role of S1P 2 in vascular barrier integrity and anaphylaxis is not well understood. Endothelial nitric oxide synthase (eNOS) generates nitric oxide to mediate vascular leakage, compromising survival in patients with anaphylaxis. We recently observed that endothelial S1P2 inhibits Akt, an activating kinase of eNOS. Objective We tested the hypothesis that endothelial S1P 2 might suppress eNOS, exerting a protective effect against endothelial barrier disruption and anaphylaxis. Methods Mice deficient in S1P2 and eNOS underwent antigen challenge or platelet-activating factor (PAF) injection. Analyses were performed to examine vascular permeability and the underlying mechanisms. Results S1pr2 deletion augmented vascular leakage and lethality after either antigen challenge or PAF injection. PAF injection induced activation of Akt and eNOS in the aortas and lungs of S1pr2-null mice, which were augmented compared with values seen in wild-type mice. Consistently, PAF-induced increase in cyclic guanosine monophosphate levels in the aorta was enhanced in S1pr-null mice. Genetic Nos3 deletion or pharmacologic eNOS blockade protected S1pr2-null mice from aggravation of barrier disruption after antigen challenge and PAF injection. ECs isolated from S1pr2-null mice exhibited greater stimulation of Akt and eNOS, with enhanced nitric oxide production in response to sphingosine-1-phosphate or PAF, compared with that seen in wild-type ECs. Moreover, S1pr2-deficient ECs showed more severe disassembly of adherens junctions with augmented S-nitrosylation of β-catenin in response to PAF, which was restored by pharmacologic eNOS blockade. Conclusion S1P2 diminishes harmful robust eNOS stimulation and thereby attenuates vascular barrier disruption, suggesting potential usefulness of S1P2 agonists as novel therapeutic agents for anaphylaxis. © 2013 American Academy of Allergy, Asthma & Immunology.
DOI: 10.1016/j.jaci.2013.07.026
URI: http://hdl.handle.net/2297/36259
関連URI: http://www.elsevier.com/locate/issn/00916749
資料種別: Journal Article
版表示: author
出現コレクション:1. 査読済論文(医学・保健)

このアイテムを引用あるいはリンクする場合は次の識別子を使用してください。 http://hdl.handle.net/2297/36259

本リポジトリに保管されているアイテムはすべて著作権により保護されています。

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2010  Duraspace - ご意見をお寄せください